Special Counsel Jill Wright was quoted in a Modern Healthcare article, “HHS Investigators Will Prioritize Causes for High Drug Prices in 2017,” on November 11, 2016. The article discussed top issues U.S. Department of Health and Human Services Office of Inspector General (OIG) hopes to tackle in 2017, including a heightened focus on drug costs. One area the agency plans to review is whether the Centers for Medicare & Medicaid Services can save money if U.S. providers purchased smaller-size single-use drug vials that are used in other countries.
Wright said OIG might see the vial issue as a relatively simple way to curb waste for both providers and payers, and also represents a chance to bring the issue to the FDA, which approves vial sizes. She said, “It’s something that seems to be easy to do, and it might be sort of low-hanging fruit as far as preventing tax payers dollars from being wasted.”
Wright said OIG might see the vial issue as a relatively simple way to curb waste for both providers and payers, and also represents a chance to bring the issue to the FDA, which approves vial sizes. She said, “It’s something that seems to be easy to do, and it might be sort of low-hanging fruit as far as preventing tax payers dollars from being wasted.”
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”